149 363

Cited 43 times in

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Authors
Kim, YR; Kim, JS; Min, YH; Hyunyoon, D; Shin, HJ; Mun, YC; Park, Y; Do, YR; Jeong, SH; Park, JS; Oh, SY; Lee, S; Park, EK; Jang, JS; Lee, WS; Lee, HW; Eom, H; Ahn, JS; Jeong, JH; Baek, SK; Kim, SJ; Kim, WS; Suh, C
Citation
Journal of hematology & oncology, 5:49-49, 2012
Journal Title
Journal of hematology & oncology
ISSN
1756-8722
Abstract
BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.



METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed.



RESULTS: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001).



CONCLUSIONS: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.
MeSH terms
AdultAgedAntibodies, Monoclonal, Murine-Derived/administration & dosageAntineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic useCohort StudiesCyclophosphamide/administration & dosageDoxorubicin/administration & dosageHumansLymphoma, Large B-Cell, Diffuse/*drug therapy/mortality/pathologyMiddle AgedPrednisone/administration & dosagePrognosisRetrospective StudiesSurvival RateTreatment OutcomeVincristine/administration & dosage
DOI
10.1186/1756-8722-5-49
PMID
22889180
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
정, 성현
Full Text Link
Files in This Item:
22889180.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse